Welcome to our dedicated page for Abbvie SEC filings (Ticker: ABBV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
AbbVie Inc. filings document formal disclosures for a global pharmaceutical issuer with common stock and multiple senior note series registered on the New York Stock Exchange. Recent Form 8-K reports cover quarterly and annual results, preliminary earnings impacts from acquired IPR&D and milestone expenses, material-event disclosures, material agreements and capital-structure updates.
The company’s filing record also includes debt-financing disclosures for completed senior note offerings and definitive proxy materials covering board matters, executive compensation, equity awards and shareholder voting items. These documents provide regulatory detail on AbbVie’s operating results, listed securities, governance framework and financing activity.
AbbVie Inc. updated its 2026 earnings guidance to reflect second-quarter 2026 acquired IPR&D and milestones expense of $291 million, which is expected to reduce reported GAAP and adjusted non-GAAP diluted EPS by $0.17 per share. The company now expects full-year 2026 adjusted diluted EPS of $13.91–$14.11, compared with previously announced guidance that excluded this second-quarter expense. For the quarter ended June 30, 2026, AbbVie’s adjusted diluted EPS guidance range is $3.57–$3.61, also including the impact of the same $291 million expense. These figures are preliminary and subject to completion of regular financial closing procedures.
AbbVie Inc. director Edward J. Rapp reported receiving a grant of stock equivalent units as part of his board compensation. He acquired 134 stock equivalent units on June 30, 2026 at a reference value of $251.64 per unit, each tied to AbbVie common stock. Following this grant, his reported balance increased to 29,236 stock equivalent units, which earn the same return as if the fees were invested directly in AbbVie stock and include units added through a dividend reinvestment feature. These units are credited to a director grantor trust and are scheduled to be distributed over a period equal to his years of board service, generally beginning at the later of age 65 or retirement from the board.
AbbVie Inc. director Susan E. Quaggin reported a compensation-related award of stock equivalent units. On the reported date, she acquired 62 stock equivalent units tied to AbbVie common stock at 251.64 per unit, bringing her total balance to 853 stock equivalent units held directly.
The footnotes explain that director fees are credited to an unfunded book account in the director's name and are distributed over a period equal to the director's years of board service, generally starting at the later of age 65 or retirement from the board. These stock equivalent units earn the same return as if the fees were invested in AbbVie stock and the reported balance also includes units acquired through a dividend reinvestment feature.
AbbVie Inc. is expanding its immunology and respiratory portfolio by agreeing to acquire Apogee Therapeutics and its pipeline of clinical-stage antibody drugs. AbbVie will purchase all outstanding Apogee shares for $135.11 in cash per share, valuing the company at about $10.9 billion. The deal, unanimously approved by both boards, is expected to close in the third quarter of 2026, subject to Apogee shareholder and regulatory approvals.
Apogee’s lead asset, zumilokibart (APG777), has shown strong Phase 2 results in atopic dermatitis, with roughly two-thirds of treated patients achieving significant skin clearance at 16 weeks and supporting infrequent maintenance dosing. AbbVie expects the transaction to be accretive to its adjusted diluted earnings per share beginning in 2032 and highlights potential “mega-blockbuster” peak sales across Apogee’s pipeline, including combination program APG273 for asthma.
AbbVie filed a Form 144 notice to sell 13,000 shares of common stock on 05/26/2026. The filing lists an aggregate offering price of $2,781,990.90 and reports 1,766,792,821 shares outstanding in the same line. The broker listed is Morgan Stanley Smith Barney LLC at 1 New York Plaza, New York.
The filing identifies multiple blocks of restricted stock by grant date and share counts: 2,535 (05/06/2013), 2,764 (05/09/2014), 2,187 (05/08/2015), 2,974 (05/06/2016), and 2,540 (05/05/2017). The document is a sale notice under Form 144 and lists the NYSE as the exchange.
AbbVie Inc. reported the results of its 2026 Annual Meeting of Stockholders, held on May 8, 2026. Stockholders voted on the election of directors and several other matters.
Director nominees including Jennifer L. Davis, Melody B. Meyer, Robert A. Michael, and Frederick H. Waddell each received more than 1.21 billion votes in favor, with substantially fewer votes against or abstaining, alongside significant broker non-votes. Additional proposals received vote totals such as 1,522,575,012 for and 23,766,564 against on one item, and other items with for votes ranging from about 515.6 million to over 1.29 billion, all with recorded against, abstain, and broker non-vote counts.
FALK THOMAS J reported acquisition or exercise transactions in this Form 4 filing.
AbbVie Inc. director Thomas J. Falk reported a compensation-related equity grant. He received 1,118 shares of AbbVie common stock at $0.00 per share as a grant of restricted stock units under the AbbVie Amended and Restated 2013 Incentive Stock Program. Following this award, he holds 2,321 AbbVie shares directly. The restricted stock units will be settled one-for-one in AbbVie shares upon the earlier of his separation from service, death, or a change in control as defined in the program. Separately, an additional 3,000 shares are owned indirectly through a limited partnership jointly controlled by Falk and his spouse, for which he disclaims beneficial ownership except for his pecuniary interest.
WADDELL FREDERICK H reported acquisition or exercise transactions in this Form 4 filing.
AbbVie Inc. director Frederick H. Waddell received an equity grant of 1,118 shares of AbbVie common stock in the form of restricted stock units. The award was granted at no cash cost to him as part of AbbVie’s incentive stock program.
The restricted stock units will be settled on a one-to-one basis in AbbVie shares upon the earlier of his separation from service, death, or a change in control as defined in the program. Following this grant, he directly holds 30,076 AbbVie shares.
Roberts Rebecca B reported acquisition or exercise transactions in this Form 4 filing.
AbbVie Inc. director Rebecca B. Roberts received a grant of 1,118 shares of common stock in the form of restricted stock units. These units were awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program and carry a zero-dollar grant price. After this grant, she directly holds 14,846 shares. The units will be settled on a one‑for‑one basis in AbbVie common stock upon the earlier of her separation from service, death, or a change in control as defined in the program.
AbbVie Inc. director Edward J. Rapp received an award of 1,118 restricted stock units under the AbbVie Amended and Restated 2013 Incentive Stock Program. Each unit will convert into one share of AbbVie common stock on the earlier of his separation from service, death, or a change in control as defined in the program. Following this grant, Rapp holds 45,964 AbbVie shares directly, including 10,388 shares previously held indirectly through a spouse’s trust that are now held directly.